Thiogenesis Therapeutics Corp (TSE:TTI) has released an update.
Thiogenesis Therapeutics Corp. has partnered with UC San Diego to advance a Phase 2 clinical trial for TTI-0102, a promising treatment for pediatric NASH, a severe liver condition with no current approved medications. The treatment, leveraging an existing drug’s safety data, aims to alleviate liver inflammation and scarring in children, with plans to assess improvements and safety over a 12-week trial period.
For further insights into TSE:TTI stock, check out TipRanks’ Stock Analysis page.
